Sign In
Buy WST
West Pharmaceutical Services Earnings Calls
| Release date | Apr 23, 2026 |
| EPS estimate | $1.68 |
| EPS actual | $2.13 |
| EPS Surprise | 26.79% |
| Revenue estimate | 780.312M |
| Revenue actual | 844.9M |
| Revenue Surprise | 8.28% |
| Release date | Feb 12, 2026 |
| EPS estimate | $1.83 |
| EPS actual | $2.04 |
| EPS Surprise | 11.48% |
| Revenue estimate | 794.89M |
| Revenue actual | 805M |
| Revenue Surprise | 1.27% |
| Release date | Oct 23, 2025 |
| EPS estimate | $1.68 |
| EPS actual | $1.96 |
| EPS Surprise | 16.67% |
| Revenue estimate | 785.708M |
| Revenue actual | 804.3M |
| Revenue Surprise | 2.37% |
| Release date | Jul 24, 2025 |
| EPS estimate | $1.51 |
| EPS actual | $1.84 |
| EPS Surprise | 21.85% |
| Revenue estimate | 726.091M |
| Revenue actual | 766.2M |
| Revenue Surprise | 5.52% |
Last 4 Quarters for West Pharmaceutical Services
Below you can see how WST performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 24, 2025 |
| Price on release | $279.10 |
| EPS estimate | $1.51 |
| EPS actual | $1.84 |
| EPS surprise | 21.85% |
| Date | Price |
|---|---|
| Jul 18, 2025 | $210.89 |
| Jul 21, 2025 | $210.08 |
| Jul 22, 2025 | $218.90 |
| Jul 23, 2025 | $227.31 |
| Jul 24, 2025 | $279.10 |
| Jul 25, 2025 | $263.51 |
| Jul 28, 2025 | $257.76 |
| Jul 29, 2025 | $252.94 |
| Jul 30, 2025 | $249.21 |
| 4 days before | 32.34% |
| 4 days after | -10.71% |
| On release day | -5.59% |
| Change in period | 18.17% |
| Release date | Oct 23, 2025 |
| Price on release | $307.25 |
| EPS estimate | $1.68 |
| EPS actual | $1.96 |
| EPS surprise | 16.67% |
| Date | Price |
|---|---|
| Oct 17, 2025 | $270.60 |
| Oct 20, 2025 | $274.90 |
| Oct 21, 2025 | $279.39 |
| Oct 22, 2025 | $277.00 |
| Oct 23, 2025 | $307.25 |
| Oct 24, 2025 | $297.47 |
| Oct 27, 2025 | $287.22 |
| Oct 28, 2025 | $283.49 |
| Oct 29, 2025 | $284.86 |
| 4 days before | 13.54% |
| 4 days after | -7.29% |
| On release day | -3.18% |
| Change in period | 5.27% |
| Release date | Feb 12, 2026 |
| Price on release | $243.61 |
| EPS estimate | $1.83 |
| EPS actual | $2.04 |
| EPS surprise | 11.48% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $248.95 |
| Feb 09, 2026 | $248.93 |
| Feb 10, 2026 | $243.56 |
| Feb 11, 2026 | $246.16 |
| Feb 12, 2026 | $243.61 |
| Feb 13, 2026 | $250.49 |
| Feb 17, 2026 | $243.19 |
| Feb 18, 2026 | $248.26 |
| Feb 19, 2026 | $243.83 |
| 4 days before | -2.15% |
| 4 days after | 0.0903% |
| On release day | 2.82% |
| Change in period | -2.06% |
| Release date | Apr 23, 2026 |
| Price on release | $309.30 |
| EPS estimate | $1.68 |
| EPS actual | $2.13 |
| EPS surprise | 26.79% |
| Date | Price |
|---|---|
| Apr 17, 2026 | $273.73 |
| Apr 20, 2026 | $278.00 |
| Apr 21, 2026 | $274.72 |
| Apr 22, 2026 | $274.38 |
| Apr 23, 2026 | $309.30 |
| Apr 24, 2026 | $306.16 |
| Apr 27, 2026 | $302.20 |
| Apr 28, 2026 | $292.13 |
| Apr 29, 2026 | $295.36 |
| 4 days before | 12.99% |
| 4 days after | -4.51% |
| On release day | -1.02% |
| Change in period | 7.90% |
West Pharmaceutical Services Earnings Call Transcript Summary of Q1 2026
West reported a very strong Q1 2026: revenue $845M (+21% reported, +15% organic) and adjusted EPS $2.13 (+47% Y/Y), both well above expectations. Management raised full-year guidance: organic revenue growth now 7%–9% and adjusted EPS $8.40–$8.75. The outperformance was broad-based but led by HVP (high-value primary) components, which grew ~23% organic—driven by GLP-1 elastomers (GLP-1 HVPs contributed ~10% of company sales) and robust biologics/biosimilar demand (NovaPure strength). Annex 1 conversions and other HVP upgrades are cited as multi‑year tailwinds (management expects ~200 bps revenue contribution in 2026) and operational-excellence initiatives are being scaled across European sites to ramp output faster than previously planned. HVP delivery devices (+28% organic) and West Vantage (contract manufacturing/drug handling) grew, with Dublin site now operational. Gross margin expanded to 35.1% and adjusted operating margin to 21.4% (up 350 bps Y/Y); management expects further margin expansion for the year despite commodity and fuel pressure and has mitigation plans. Financial position is strong: Q1 operating cash flow $90M, capex guidance $250M–$275M, $521M cash, and a new $1B share repurchase program (Q1 buybacks: 1.2M shares for $298M) plus dividends paid. Management reiterated the expected midyear close of the SmartDose transaction and emphasized prudence given macro volatility. CEO succession search is underway with an anticipated appointment in H2 2026.
